{"id":814289,"date":"2025-02-18T12:12:19","date_gmt":"2025-02-18T17:12:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/"},"modified":"2025-02-18T12:12:19","modified_gmt":"2025-02-18T17:12:19","slug":"regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/","title":{"rendered":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n BENSALEM, Pa.<\/span>
\n <\/span>, Feb. 18, 2025<\/span><\/span> \/PRNewswire\/ — The Law Offices of Howard G. Smith<\/span><\/a> announces that investors with substantial losses have opportunity to lead the securities fraud<\/span> class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN<\/a>).<\/p>\n

\n IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), <\/b>
\n CONTACT THE LAW OFFICES OF HOWARD G. SMITH\u00a0BEFORE MARCH 10, 2025<\/span><\/b>
\n (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD<\/span> LAWSUIT.<\/b>\n <\/p>\n

Contact the Law Offices of Howard G. Smith<\/span> to discuss your legal rights by email at\u00a0howardsmith@howardsmithlaw.com<\/a>, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com<\/a>.<\/p>\n

\n What Is The Lawsuit About?
<\/b>The complaint filed alleges<\/span> that, between November 2, 2023<\/span> and October 30, 2024<\/span>, Defendants failed to disclose to investors: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron’s price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n

\n Contact Us To Participate or Learn More: \u00a0<\/b>\n <\/p>\n

If you wish to\u00a0learn more\u00a0about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.<\/span>,
Law Offices of Howard G. Smith<\/span>,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania<\/span> 19020,
Call us at: (215) 638-4847
Email us at: howardsmith@howardsmithlaw.com<\/a>,
Visit our website at: www.howardsmithlaw.com<\/a>.<\/p>\n

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\n Contact Us: <\/b>\n <\/p>\n

Law Offices of Howard G. Smith<\/span>
Howard G. Smith, Esquire<\/span>
215-638-4847
howardsmith@howardsmithlaw.com<\/a>
www.howardsmithlaw.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302377739.html<\/a><\/p>\n

SOURCE Law Offices of Howard G. Smith<\/span><\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BENSALEM, Pa. , Feb. 18, 2025 \/PRNewswire\/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH\u00a0BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at\u00a0howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Is The Lawsuit About? The complaint filed alleges that, between November 2, 2023 … <\/p>\n

Continue reading “Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814289","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRegeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BENSALEM, Pa. , Feb. 18, 2025 \/PRNewswire\/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH\u00a0BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at\u00a0howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Is The Lawsuit About? The complaint filed alleges that, between November 2, 2023 … Continue reading "Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-18T17:12:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit\",\"datePublished\":\"2025-02-18T17:12:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/\"},\"wordCount\":452,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH20328&sd=2025-02-18\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/\",\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH20328&sd=2025-02-18\",\"datePublished\":\"2025-02-18T17:12:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH20328&sd=2025-02-18\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=PH20328&sd=2025-02-18\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire BENSALEM, Pa. , Feb. 18, 2025 \/PRNewswire\/ — The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH\u00a0BEFORE MARCH 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at\u00a0howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com. What Is The Lawsuit About? The complaint filed alleges that, between November 2, 2023 … Continue reading \"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-18T17:12:19+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit","datePublished":"2025-02-18T17:12:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/"},"wordCount":452,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/","name":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18","datePublished":"2025-02-18T17:12:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH20328&sd=2025-02-18"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-regn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814289"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814289\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}